Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis

References

• FolkmanJAnti-angiogenesis: new concept for therapy of solid tumorsAnn Surg197217534094165077799
   PubMed Web of Science ®Google Scholar
• CarmelietPJainRKAngiogenesis in cancer and other diseasesNature2000407680124925711001068
   PubMed Web of Science ®Google Scholar
• FolkmanJRole of angiogenesis in tumor growth and metastasisSemin Oncol2002296 suppl 16151812516034
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTECellaDPazopanib versus sunitinib in metastatic renal-cell carcinomaN Engl J Med2013369872273123964934
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBTomczakPAxitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trialLancet Oncol201314655256223598172
   PubMed Web of Science ®Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol20102861061106820100962
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med2007356212513417215530
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPTARGET Study GroupSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
   PubMed Web of Science ®Google Scholar
• RaymondEDahanLRaoulJLSunitinib malate for the treatment of pancreatic neuroendocrine tumorsN Engl J Med2011364650151321306237
   PubMed Web of Science ®Google Scholar
• DemetriGDvan OosteromATGarrettCREfficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialLancet200636895441329133817046465
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• LamETRingelMDKloosRTPhase II clinical trial of sorafenib in metastatic medullary thyroid cancerJ Clin Oncol201028142323233020368568
   PubMed Web of Science ®Google Scholar
• WellsSAGosnellJEGagelRFVandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancerJ Clin Oncol201028576777220065189
   PubMed Web of Science ®Google Scholar
• GrotheyAVan CutsemESobreroACORRECT Study GroupRegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet2013381986330331223177514
   PubMed Web of Science ®Google Scholar
• DemetriGDReichardtPKangYKGRID Study InvestigatorsEfficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet2013381986329530223177515
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOFouadMRisk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysisExpert Rev Anticancer Ther201515112914125482593
   PubMed Web of Science ®Google Scholar
• FischerAWuSHoALLacoutureMEThe risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysisInvest New Drugs201331378779723345001
   PubMed Web of Science ®Google Scholar
• EltingLSChangYCParelkarPMucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysisSupport Care Cancer201321113243325423636648
   PubMed Web of Science ®Google Scholar
• BalagulaYWuSSuXFeldmanDRLacoutureMEThe risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysisInvest New Drugs20123041773178121394443
   PubMed Web of Science ®Google Scholar
• IacovelliRPalazzoAProcopioGIncidence and relative risk of hepatic toxicity in patients treated with antiangiogenic tyrosine kinase inhibitors for malignancyBr J Clin Pharmacol201377692993823981115
   PubMed Web of Science ®Google Scholar
• GhataliaPJeYMouallemNEHepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of randomized clinical trialsCrit Rev Oncol Hematol201493325727625523486
   PubMed Web of Science ®Google Scholar
• TeoYLHoHKChanARisk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysisCancer Treat Rev201339219920623099278
   PubMed Web of Science ®Google Scholar
• KapadiaSHapaniSChoueiriTKWuSRisk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patientsActa Oncol20135261202121223594201
   PubMed Web of Science ®Google Scholar
• QiWXSunYJTangLNShenZYaoYRisk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysisCrit Rev Oncol Hematol201489339440324182420
   PubMed Web of Science ®Google Scholar
• QiWXShenFQingZXiao-MaoGRisk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysisTumour Biol20143511107151072225070487
   PubMed Web of Science ®Google Scholar
• GhataliaPMorganCJJeYCongestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitorsCrit Rev Oncol Hematol201494222823725577572
   PubMed Web of Science ®Google Scholar
• GhataliaPJeYKaymakcalanMDSonpavdeGChoueiriTKQTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitorsBr J Cancer2014112229630525349964
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOFouadMRisk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysisFuture Oncol201410121981199225386814
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOFouadMRisk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysisCrit Rev Oncol Hematol201492319420725028151
   PubMed Web of Science ®Google Scholar
• QiWXShenZTangLNYaoYRisk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysisCrit Rev Oncol Hematol2014922718224878433
   PubMed Web of Science ®Google Scholar
• QiWXShenZTangLNYaoYCongestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trialsBr J Clin Pharmacol201478474876224661224
   PubMed Web of Science ®Google Scholar
• QiWXShenZLinFIncidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trialsBr J Clin Pharmacol201375491993022882307
   PubMed Web of Science ®Google Scholar
• QiWXMinDLShenZRisk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysisInt J Cancer2013132122967297423225494
   PubMed Web of Science ®Google Scholar
• JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials19961711128721797
   PubMedGoogle Scholar
• MoherDLiberatiATetzlaffJAltmanDGGroupPPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementJ Clin Epidemiol200962101006101219631508
   PubMed Web of Science ®Google Scholar
• ChoueiriTKSchutzFAJeYRosenbergJEBellmuntJRisk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trialsJ Clin Oncol201028132280228520351323
   PubMed Web of Science ®Google Scholar
• ZintzarasEIoannidisJPHeterogeneity testing in meta-analysis of genome searchesGenet Epidemiol200528212313715593093
   PubMed Web of Science ®Google Scholar
• ReckMKaiserRMellemgaardALUME-Lung 1 Study GroupDocetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialLancet Oncol201415214315524411639
   PubMed Web of Science ®Google Scholar
• LaurieSASolomonBJSeymourLRandomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29Eur J Cancer201450470671224360368
   PubMed Web of Science ®Google Scholar
• GaronEBCiuleanuTEArrietaORamucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialLancet2014384994466567324933332
   PubMed Web of Science ®Google Scholar
• ScagliottiGVVynnychenkoIParkKInternational, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1J Clin Oncol201230232829283622753922
   PubMed Web of Science ®Google Scholar
• ScagliottiGVKrzakowskiMSzczesnaASunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trialJ Clin Oncol201230172070207822564989
   PubMed Web of Science ®Google Scholar
• LeeJSHirshVParkKVandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)J Clin Oncol201230101114112122370318
   PubMed Web of Science ®Google Scholar
• NataleRBThongprasertSGrecoFAPhase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancerJ Clin Oncol20112981059106621282542
   PubMed Web of Science ®Google Scholar
• ScagliottiGNovelloSvon PawelJPhase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancerJ Clin Oncol201028111835184220212250
   PubMed Web of Science ®Google Scholar
• HerbstRSSunYEberhardtWEVandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trialLancet Oncol201011761962620570559
   PubMed Web of Science ®Google Scholar
• NataleRBBodkinDGovindanRVandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii studyJ Clin Oncol200927152523252919332730
   PubMed Web of Science ®Google Scholar
• CarratoASwieboda-SadlejAStaszewska-SkurczynskaMFluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trialJ Clin Oncol201331101341134723358972
   PubMed Web of Science ®Google Scholar
• HoffPMHochhausAPestalozziBCCediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II)J Clin Oncol201230293596360322965965
   PubMed Web of Science ®Google Scholar
• BroseMSNuttingCMJarzabBSorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialLancet2014384994031932824768112
   PubMed Web of Science ®Google Scholar
• WellsSAJrRobinsonBGGagelRFVandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trialJ Clin Oncol201230213414122025146
   PubMed Web of Science ®Google Scholar
• LeboulleuxSBastholtLKrauseTVandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trialLancet Oncol201213989790522898678
   PubMed Web of Science ®Google Scholar
• KudoMHanGFinnRSBrivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase 3 trialHepatology20146051697170724996197
   PubMed Web of Science ®Google Scholar
• Abou-AlfaGKJohnsonPKnoxJJDoxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trialJAMA2010304192154216021081728
   PubMed Web of Science ®Google Scholar
• BarriosCHLiuMCLeeSCPhase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancerBreast Cancer Res Treat2010121112113120339913
   PubMed Web of Science ®Google Scholar
• ChoueiriTKRossRWJacobusSDouble-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancerJ Clin Oncol201230550751222184381
   PubMed Web of Science ®Google Scholar
• GoncalvesAGilabertMFrancoisEBAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancerAnn Oncol201223112799280522771827
   PubMed Web of Science ®Google Scholar
• YiJHLeeJParkSHRandomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinumBr J Cancer201210691469147422460270
   PubMed Web of Science ®Google Scholar
• FlahertyKTLeeSJZhaoFPhase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanomaJ Clin Oncol201331337337923248256
   PubMed Web of Science ®Google Scholar
• HutsonTEEscudierBEstebanERandomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinomaJ Clin Oncol201432876076724297950
   PubMed Web of Science ®Google Scholar
• ServeHKrugUWagnerRSorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trialJ Clin Oncol201331253110311823897964
   PubMed Web of Science ®Google Scholar
• MichaelsonMDOudardSOuYCRandomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancerJ Clin Oncol2014322768224323035
   PubMed Web of Science ®Google Scholar